Search research articles
Contact Us
Filters
Showing results (571-580 of 622) with videos related to
Page
of 63
Sort By:
Muscle & Nerve
|
July 23, 2022
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Albert Gil-Vila, Naveen Ravichandran, Albert Selva-O'Callaghan, et al.
The European Respiratory Journal
|
November 5, 2021
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Marius M Hoeper, Christine Pausch, Karen M Olsson, et al.
International Journal of Rheumatic Diseases
|
March 5, 2023
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
Samuel Katsuyuki Shinjo, Minchul Kim, Leonardo Santos Hoff, et al.
Rheumatology International
|
September 5, 2023
Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey
Sakir Ahmed, Latika Gupta, Masataka Kuwana, et al.
Annals of the Rheumatic Diseases
|
August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study
Gabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
The Lancet. Rheumatology
|
December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Lorinda Chung, Cathie Spino, Richard McLain, et al.
Rheumatology International
|
August 14, 2022
COVAD survey 2 long-term outcomes: unmet need and protocol
Zoha Zahid Fazal, Parikshit Sen, Mrudula Joshi, et al.
Annals of the Rheumatic Diseases
|
January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
Journal of the American Heart Association
|
February 26, 2025
Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Andrea-Hermina Györfi, Tim Filla, Amin Polzin, et al.
The Lancet. Rheumatology
|
January 24, 2024
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Anna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, et al.
Page
of 63
Search research articles
Search
Showing results (571-580 of 622) with videos related to
Sort By:
Page
of 63
Muscle & Nerve
|
July 23, 2022
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Albert Gil-Vila, Naveen Ravichandran, Albert Selva-O'Callaghan, et al.
The European Respiratory Journal
|
November 5, 2021
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Marius M Hoeper, Christine Pausch, Karen M Olsson, et al.
International Journal of Rheumatic Diseases
|
March 5, 2023
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
Samuel Katsuyuki Shinjo, Minchul Kim, Leonardo Santos Hoff, et al.
Rheumatology International
|
September 5, 2023
Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey
Sakir Ahmed, Latika Gupta, Masataka Kuwana, et al.
Annals of the Rheumatic Diseases
|
August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study
Gabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
The Lancet. Rheumatology
|
December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Lorinda Chung, Cathie Spino, Richard McLain, et al.
Rheumatology International
|
August 14, 2022
COVAD survey 2 long-term outcomes: unmet need and protocol
Zoha Zahid Fazal, Parikshit Sen, Mrudula Joshi, et al.
Annals of the Rheumatic Diseases
|
January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
Journal of the American Heart Association
|
February 26, 2025
Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Andrea-Hermina Györfi, Tim Filla, Amin Polzin, et al.
The Lancet. Rheumatology
|
January 24, 2024
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Anna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, et al.
Page
of 63